Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

[PDMR] [PDX] [699152-130-R] Pancreatic Adenocarcinoma

ABSTRACT:

SUBMITTER:

PROVIDER: S-CMO4125 | biostudies-other |

REPOSITORIES: biostudies-other

ACCESS DATA

Json Xml

Similar Datasets

Gene Expression data from Pdx-1CreAPC+/LP53L/L pancreatic ductal adenocarcinoma (PDAC) cells versus Pdx-1CreP53L/L normal pancreatic ductal cells

Project description:Analysis of primary PDAC cells established from Pdx-1CreAPCL/+p53L/L and Pdx-1Crep53L/L mice. APC haploinsufficiency combined with P53 loss in the pancreas drives MCN progression in mice. Results provide insight into molecular mechanisms invloved in the MCN formation of Pdx-1Cre APCL/+P53L/L mice. Pdx-1CreAPC+/LP53L/L PDAC cell lines and 2 Pdx-1CreP53L/L ductal cell lines were analyzed.

2014-10-01 | E-GEOD-61894 | biostudies-arrayexpress

Dinaciclib prolongs survival in the LSL-KrasG12D/+ ; LSL-Trp53R172H/+ ; Pdx-1-Cre (KPC) transgenic murine models of pancreatic ductal adenocarcinoma.

Project description: Not available

| S-EPMC7137051 | biostudies-literature

Gene Expression data from Pdx-1CreAPC+/LP53L/L pancreatic ductal adenocarcinoma (PDAC) cells versus Pdx-1CreP53L/L normal pancreatic ductal cells

2014-10-01 | GSE61894 | GEO

[PDMR] [organoid] [699152-130-R-V1-organoid] Pancreatic Adenocarcinoma

Project description: Not available

| S-CMO4955 | biostudies-other

[PDMR] [PDX] [866234-130-R] Rectal Adenocarcinoma

Project description: Not available

| S-CMO4984 | biostudies-other

[PDMR] [cell line] [699152-130-R-J1-PDC] Pancreatic Adenocarcinoma

Project description: Not available

| S-CMO5774 | biostudies-other

Pancreatic ductal adenocarcinoma

Project description:Pancreatic ductal adenocarcinoma

| PRJNA432344 | ENA

Acute and chronic treatment of trametinib plus lapatinib in patient-derived xenografts (PDX) of pancreatic adenocarcinoma (PDAC)

Project description:Pancreatic ductal adenocarcinoma (PDAC) is a deadly disease with limited effective treatment options. PDAC tumors frequently harbor the constitutively activated form of KRAS which drives proliferative signaling, but directly targeting KRAS has so far been unsuccessful. To overcome this limitation, combinatorial treatment strategies have been developed to inhibit upstream activators and downstream effectors of KRAS signaling. One such combination using trametinib, a MEK1/2 inhibitor, and lapatinib, an EGFR/HER2 inhibitor, substantially reduced tumor growth in a patient-derived xenograft (PDX) model of PDAC. Although trametinib and lapatinib are both known to inhibit the canonical MAPK signaling cascade, the effects of this combination on other important pathways in pancreatic cancer remains unclear. To investigate this, we analyze global gene expression profiles from PDX models of PDAC treated with trametinib, lapatinib, or their combination. Our results show that trametinib induces similar yet less significant expression changes compared to combination while lapatinib has little to no effect as a monotherapy in the acute treatment setting. In the chronic treatment setting, we show that tumors exposured to prolonged treatment with trametinib plus lapatinib eventually leads to adapative resistance. Expression analyses of resistant tumors revealed concominant gene expression changes in upstream receptor tyrosine kinases (RTKs).

2017-05-02 | GSE98399 | GEO

Targeting Interleukin-6/Glycoprotein-130 Signaling by Raloxifene or SC144 Enhances Paclitaxel Efficacy in Pancreatic Cancer.

Project description: Not available

| S-EPMC9856922 | biostudies-literature

Efficient growth suppression in pancreatic cancer PDX model by fully human anti-mesothelin CAR-T cells.

Project description: Not available

| S-EPMC5712292 | biostudies-literature